MAP2K7 and acute myeloid leukemia: Unesbulin (PTC596) is a second-generation BMI-1 inhibitor that downregulates MCL-1 expression in AML cells and may influence expression of MCL1 inducers including MEK, ERK, AKT, STAT3, and STAT5 [29].